Leena Laasonen

Helsinki University Hospital — Finland

Biochemistry, Genetics and Molecular Biology · Life Sciences

32h-index4.9kcitations160works8.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(66), Cancer Research and Treatments(53), Rheumatoid Arthritis Research and Therapies(36), CAR-T cell therapy research(33), Viral Infectious Diseases and Gene Expression in Insects(29)

Publications160 total

Rare coding variants in NOX4 link high ROS levels to psoriatic arthritis mutilans
EMBO Molecular Medicine·2024· 8 citedOpen Access
Rare coding variants in <i>NOX4</i> link high superoxide levels to psoriatic arthritis mutilans
2023Open Access
Supplementary Figure Legend from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Data from Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
2023Open Access
Supplementary Figure 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 4 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 4 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure Legend from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Data from Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
2023Open Access
Supplementary Figure 5 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Data from Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
2023Open Access
Supplementary Figure 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 5 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Marjatta Leirisalo‐Repo(18), Akseli Hemminki(13), Timo Joensuu(12), Pekka Hannonen(11), Hannu Kautiainen(11), Lotta Kangasniemi(11), Vincenzo Cerullo(11), Minna Oksanen(10), Anna Kanerva(10), Timo Möttönen(9), Markku Korpela(8), Leena Paimela(8), Sophie Escutenaire(8), Iulia Diaconu(8), Petri Nokisalmi(8), Elina Haavisto(8), Kaarina Partanen(8), Sari Pesonen(7), Aila Karioja‐Kallio(7), Maria Rajecki(6)